BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » iPS Cells » Page 10

The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD

By Leave a Comment

In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogeneic cell therapy solutions, is tackling these obstacles head-on with its novel induced pluripotent stem cell (iPSC) technologies. In this interview, Stefan Braam, PhD, Founder & Chief Technical Officer of Cellistic, shares insights into the company’s journey, its innovative platforms—including Pulse™, Echo™, and the newly introduced Allo Chassis™—and how these advancements are poised to redefine cell therapy development as we known it.

With a clear focus on efficiency, cost reduction, and clinical translation, Cellistic is at the forefront of making off-the-shelf, immune-cloaked cell therapies a reality. Enjoy! [Read more…]

Human Induced Pluripotent Stem Cell (iPSC) Derived Tissues – Present & Future Outlook

By Leave a Comment

In this article, the present and future outlook for human iPSC-derived tissues is explored. Induced pluripotent stem cells (iPSCs) are differentiated cells that are reprogrammed into a pluripotent state, allowing a wide range of cell and tissue types to be derived from them.

Key findings include:

  • iPSC technology is moving from a boutique phenomenon to industrialized cellular models.
  • Increasing recognition by industry and regulatory bodies for detecting a variety of toxicities.
  • Emerging utility for predicting cardio and neuro-related oncology adverse effects.

[Read more…]

Inside the iPSC Industry: Growth, Trends, and Future Directions

By Leave a Comment

Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells by Shinya Yamanaka’s lab at Kyoto University in Japan was the first instance in which there was successful generation of iPSCs.[1] In 2007, a series of follow-up experiments was done at Kyoto University in which human adult cells were transformed into iPSC cells. [2] Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.[3] [Read more…]

iPSC Applications in Cell Therapy, Drug Discovery, and Beyond

By Leave a Comment

Since the discovery of induced pluripotent stem cell (iPSC) technology 18 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]

iPSCs are Transforming Drug Discovery, Toxicity Testing, Disease Modeling, and Beyond

By Leave a Comment

Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using adult cells. They are derived from somatic cells by reprogramming artificially and turning on the expression of specific pluripotency genes. The reprogramming is achieved using different techniques with varying efficiencies. The iPSC technology was first discovered in 2006 by Shinya Yamanaka’s lab in Kyoto, Japan. He and his team introduced four specific genes encoding transcription factors and converted adult cells into pluripotent stem cells. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0